Dr Reddy’s receives USFDA EIR report for formulations manufacturing facilities in Duvvada, Visakhapatnam, ET HealthWorld

Hyderabad: Dr Reddy’s wrote to the National Stock Exchange of India Ltd (NSE) on the intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on the US FDA inspection at the company’s formulations manufacturing facilities (FTO-7 & FTO-9) in Duvvada, Visakhapatnam.

The company was intimated on May 17, 2024, on the inspection conducted by the United States Food & Drug Administration (US FDA) at the company’s formulations manufacturing facilities in Duvvada, Visakhapatnam, the company received the establishment inspection report (EIR).

The USFDA has classified the inspection as voluntary action indicated (VAI) and concluded that the inspection is ‘closed’ under 21 CFR 20.64(d)(3).